2024 Mary Ann Liebert Publishers Inc., Young Investigator Award
Hélène Tran, Ph.D. Research Director, Head of Antisense Oligonucleotide Therapeutics, Neurology Therapeutic Area, Servier Research Institute, France Biography: Hélène Tran is a Director in the Neuroscience Therapeutic Area at the Servier Research & Development Institute in Paris-Saclay, where she leads the antisense oligonucleotide (ASO) therapeutics ...
2024 Paper of the Year – Basic Research category
Dr. Mikyung Yu, Ph.D. Alnylam Pharmaceuticals Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates 2024 Paper of the Year – Basic Research category https://pubmed.ncbi.nlm.nih.gov/38742636/ Biography: Mikyung Yu, Ph.D., is a Principal Scientist in Research at Alnylam Pharmaceuticals. Dr. Yu led the ...
The Oligonucleotide Therapeutics Society Announces the 21st Annual Meeting in Budapest, Hungary
The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October 19–22, 2025, at the Budapest Congress Center in Budapest, Hungary. This premier global gathering of the oligonucleotide community is renowned for fostering dynamic, cross-disciplinary dialogue—bringing together leaders ...
Genome Sequencing and Gene Editing: Ancient DNA in a Living Species
Known for their large size — sometimes growing up to six feet in length — dark fur and bone-cracking back teeth, dire wolves used to be the most prominent species in continental North America (1). The canines became extinct roughly 10,000 years ago, gradually ...
Strategic IP for Oligonucleotide Therapeutics: Maximizing Innovation Value
Date: August 28, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: Strategic IP for Oligonucleotide Therapeutics: Maximizing Innovation Value Description: This talk will explore the essential elements of an effective IP strategy tailored for oligonucleotide therapeutics, balancing scientific innovation with commercial ...
The importance of involving patients in therapy development; Lessons learned from Duchenne exon skipping
Date: August 21, 2025 Time: 11-12pm EDT / 5-6pm CEST Title: The importance of involving patients in therapy development; Lessons learned from Duchenne exon skipping Description: Duchenne muscular dystrophy is a progressive muscle wasting disease caused by lack of dystrophin protein. ...
OTS Member Highlight – Masad Damha, PhD
For Masad Damha, falling in love with science was easy. Growing up in Managua, Nicaragua, his high school teachers encouraged scientific exploration, curiosity, and experimentation, such as processing vegetable oil into soap, producing hydrogen and oxygen from water via electrolysis, and determining the gravitational ...
Targeting DNA Mismatch Repair as a Potential Therapeutic Strategy for Huntington’s Disease
Huntington's disease (HD) is a devastating and fatal neurodegenerative disorder affecting movement, thinking, and behavior. In the United States alone, there are approximately 40,000 people with symptomatic Huntington's disease, and more than 200,000 are at risk of inheriting it. The fatal disease often leaves ...
FDA Approval of Vutrisiran Brings New Treatment for ATTR-CM
When Sean Riley started getting numbness in his hands, he saw a local surgeon who performed carpal tunnel surgery on both his wrists. At the time, he didn't think much of his symptoms, knowing carpal tunnel was common, he attributed his symptoms to the ...
OTS Member Highlight – David Corey, PhD
Former Oligonucleotide Therapeutics Society (OTS) President David Corey grew up being inspired by his father's love of science, noting that his father was not only good at what he did but he also enjoyed it. "I never measured myself against him because I knew ...
